Latest revenue
$627.3K
as of 2025-09-30
Latest net income
$-5.4M
as of 2025-09-30
Net margin
-857.4%
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $26.1M
- Enterprise value
- $26.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $3.26
- 52-wk low
- $0.13
- Beta
- —
- Shares out
- 8.3M
5-year trend
What this company does
Overview Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests. Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. The tests in the Company’s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patient’s…
AI summary unavailable — showing raw filing excerpt
Generated from VNRX's filing dated 2026-03-31
Key risks
Our short and long-term success is subject to numerous risks and uncertainties, many of which involve factors that are difficult to predict or beyond our control. As a result, investing in our common stock involves substantial risk. Before deciding to purchase, hold or sell our common stock, stockholders, and potential stockholders should carefully consider the risks and uncertainties described below, in addition to the other information contained in or incorporated by reference into this Report, as well as the other information we file with the SEC. If any of these risks are realized, our business, financial condition, results of operations, and prospects could be materially and adversely…
AI summary unavailable — showing raw filing excerpt
Generated from VNRX's filing dated 2026-03-31
Profitability
Operating margin
-1258.5%
42.6%Net margin
-1352.2%
38.8%Return on equity
68.2%
37.7%Return on assets
-338.4%
16.7%Leverage
Debt / equity
-1.20×
12.8%Long-term debt / equity
-0.17×
7.1%Debt / assets
596.2%
63.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $447.0K | +133.2% | $-6.3M | -3.1% | -1402.8% |
Q3 2025 2025-09-30 | $627.3K | +32.2% | $-5.4M | +7.6% | -857.4% |
Q2 2025 2025-06-30 | $406.7K | +2.8% | $-6.3M | +10.0% | -1545.2% |
Q1 2025 2025-03-31 | $246.4K | +43.6% | $-5.4M | +35.2% | -2201.3% |
Q4 2024 2024-12-31 | $191.7K | — | $-6.1M | — | -3174.2% |
Q3 2024 2024-09-30 | $474.5K | +187.2% | $-5.8M | — | -1226.8% |
Q2 2024 2024-06-30 | $395.8K | +83.0% | $-7.0M | — | -1764.9% |
Q1 2024 2024-03-31 | $171.5K | — | $-8.4M | — | -4877.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on VNRX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$267.2K
Insider selling
$0
Net activity
+$267.2K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns VNRX
Institutional value
$595.9K
Total shares held
3.0M
Distinct holders
20
-8 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1.0M | $204.8K | — | New |
| 2 | VANGUARD FIDUCIARY TRUST CO | 502.7K | $101.5K | — | New |
| 3 | BlackRock, Inc. | 446.2K | $90.1K | +1.0K (+0.2%) | Added |
| 4 | Silverberg Bernstein Capital Management LLC | 251.2K | $50.7K | +1.9K (+0.8%) | Added |
| 5 | Wealthspire Advisors, LLC | 220.0K | $44.4K | — | New |
| 6 | UBS Group AG | 207.4K | $41.9K | +207.1K (+66812.9%) | Added |
| 7 | Bank of New York Mellon Corp | 55.6K | $11.2K | +0 (+0.0%) | No change |
| 8 | GROUP ONE TRADING LLC | 50.0K | $10.1K | +0 (+0.0%) | No change |
| 9 | Cetera Investment Advisers | 40.5K | $8.2K | +20.0K (+97.3%) | Added |
| 10 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 40.0K | $8.1K | -52 (-0.1%) | Trimmed |
| 11 | Miller Financial Services LLC | 31.0K | $6.3K | — | New |
| 12 | PFG Investments, LLC | 25.0K | $5.0K | — | New |
| 13 | SANDERS MORRIS HARRIS LLC | 15.0K | $3.0K | — | New |
| 14 | Vanguard Global Advisers, LLC | 13.7K | $2.8K | — | New |
| 15 | Creative Planning | 12.8K | $2.6K | +0 (+0.0%) | No change |
| 16 | Chicago Partners Investment Group LLC | 12.0K | $1.9K | +0 (+0.0%) | No change |
| 17 | CITIGROUP INC | 8.7K | $1.8K | — | New |
| 18 | Hickory Point Bank & Trust | 5.0K | $1.0K | — | New |
| 19 | SBI Securities Co., Ltd. | 1.6K | $323 | +1.5K (+1267.5%) | Added |
| 20 | BNP PARIBAS FINANCIAL MARKETS | 265 | $54 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once VNRX's latest filing finishes processing.